Continuous glucose monitoring (CGM) has demonstrated potential in improving clinical outcomes for people with type 2 diabetes (T2D), according to a recent umbrella review published in Archives of Public Health.
The study, which included data from 989 studies and 31 articles, found that CGMs were significantly associated with better reductions in hemoglobin A1c levels compared to self-monitoring or usual care. The researchers also noted that CGMs improved glycemic variability, with a greater increase in time spent within the target range.
However, the study’s findings on patient-reported outcomes were inconclusive, and further research is needed to fully understand the effects of CGM on quality of life and other aspects of diabetes management.
The Centers for Disease Control and Prevention (CDC) estimate that approximately 38 million Americans have T2D, with about 90-95% having type 2. The disease is often associated with risk factors such as prediabetes, overweight, age, family history, physical inactivity, and ethnicity.
Recent advances in CGM technology have made the device more accessible, with some models now approved for over-the-counter (OTC) use. This has helped reduce the cost barrier, making it easier for patients to adopt this innovative treatment option.
The study’s findings are promising, but more research is needed to fully understand the benefits and limitations of CGM in diabetes management.
Source: https://www.pharmacytimes.com/view/continuous-glucose-monitoring-shows-potential-to-improving-clinical-outcomes-in-type-2-diabetes